IWA
LXRX icon

Invera Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Invera Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48K Hold
20,000
– – 0.03% 132
2026
Q1 		$31.2K Hold
20,000
– – 0.02% 98
2025
Q4 		$23K Hold
20,000
– – 0.01% 90
2025
Q3 		$27K Hold
20,000
– – 0.02% 87
2025
Q2 		$18.9K Hold
20,000
– – 0.01% 84
2025
Q1 		$9.22K Buy
+20,000
New +$12.6K 0.01% 90

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invera Wealth Advisors's LXRX Position: Q2 2026 in Review

Invera Wealth Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 20,000 shares worth $48K. The position accounts for 0.03% of the portfolio, ranked #132.

Invera Wealth Advisors first reported a position in LXRX in Q1 2025 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Invera Wealth Advisors held 20,000 shares of Lexicon Pharmaceuticals worth $48K as of Q2 2026.
  • Invera Wealth Advisors left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up 0.03% of Invera Wealth Advisors's portfolio in Q2 2026, its #132 holding.
  • Invera Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Invera Wealth Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.